Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite BioPharma (NYSE American: CANF) announced its participation in the 12th annual LD 500 Virtual Conference, scheduled for September 1, 2020. CEO Dr. Pnina Fishman will present at 9:20 AM EST and conduct private meetings with investors. The event aims to attract around 20,000 attendees and features 300 companies. Can-Fite plans to update on its advanced pipeline, including Phase III trials for rheumatoid arthritis, psoriasis, and liver cancer, alongside new studies for COVID-19 and NAFLD/NASH. Investors can register to view the presentation online.